EP3774750A1 - Immunomodulateurs, compositions et procédés associés - Google Patents

Immunomodulateurs, compositions et procédés associés

Info

Publication number
EP3774750A1
EP3774750A1 EP19780810.8A EP19780810A EP3774750A1 EP 3774750 A1 EP3774750 A1 EP 3774750A1 EP 19780810 A EP19780810 A EP 19780810A EP 3774750 A1 EP3774750 A1 EP 3774750A1
Authority
EP
European Patent Office
Prior art keywords
bis
diyl
biphenyl
dimethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19780810.8A
Other languages
German (de)
English (en)
Other versions
EP3774750A4 (fr
Inventor
Yiqian WANG
Bang Fu
Yao ZHANG
Xiangyong LIU
Jiabing Wang
Lieming Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of EP3774750A1 publication Critical patent/EP3774750A1/fr
Publication of EP3774750A4 publication Critical patent/EP3774750A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present application is concerned with pharmaceutically active compounds.
  • the disclosure provides compounds as well as their compositions and methods of use.
  • the compounds modulate PD-1/PD-L1 protein/protein interaction and are useful in the treatment of various diseases including infectious diseases and cancer.
  • the immune system plays an important role in controlling and eradicating diseases such as cancer.
  • cancer cells often develop strategies to evade or to suppress the immune system in order to favor their growth.
  • One such mechanism is altering the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al, J. Clinical Oncology 2015, 1-9) .
  • Blocking the signaling of an inhibitory immune checkpoint, such as PD-1, has proven to be a promising and effective treatment modality.
  • the interaction between PD-1 and PD-L1 results in a decrease in tumor infiltrating lymphocytes, a decrease in T-cell receptor mediated proliferation, and immune evasion by the cancerous cells (Dong et al, J. Mol Med., 81: 281-287 (2003) ; Blank et al, Cancer Immunol Immunother., 54: 307-314 (2005) ; Konishi et al, Clin. Cancer Res.. 10: 5094-5100 (2004) ) .
  • Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1, and the effect is additive when the interaction of PD-1 with PD-L2 is blocked as well (Iwai et al., Proc. Natl. Acad. Sci. USA, 99: 12293-12297 (2002) ; Brown et al, J. Immunol , 170: 1257-1266 (2003) ) .
  • PD-1 Programmed cell death-1
  • CD279 is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al, Annu. Rev. Immunol 2005, 23: 515-548; Okazaki and Honjo, Trends Immunol 2006, (4) : 195-201) . It functions as an intrinsic negative feedback system to prevent the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance.
  • PD-1 is also known to play a critical role in the suppression of antigen-specific T cell response in diseases like cancer and viral infection (Sharpe et al, Nat Immunol 2007 8, 239-245; Postow et al, J. Clinical Oncol 2015, 1-9) .
  • the structure of PD-1 consists of an extracellular immunoglobulin variable-like domain followed by a transmembrane region and an intracellular domain (Parry et al, Mol Cell Biol 2005, 9543-9553) .
  • the intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor-mediated signals.
  • PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al, Mol Cell Biol 2005, 9543-9553; Latchman et al, Nat Immunol 2001, 2, 261-268) , and they differ in their expression patterns.
  • PD-L1 protein is upregulated on macrophages and dendritic cells in response to lipopolysaccharide and GM-CSF treatment, and on T cells and B cells upon T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN- ⁇ treatment (Iwai et al, PNAS2002, 99 (19) : 12293-7; Blank et al, Cancer Res 2004, 64 (3) : 1140-5) .
  • tumor PD-Ll expression status has been shown to be prognostic in multiple tumor types (Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015; Sabatier et al, Oncotarget 2015, 6 (7) : 5449-5464) .
  • PD-L2 expression in contrast, is more restricted and is expressed mainly by dendritic cells (Nakae et al, J Immunol 2006, 177: 566-73) .
  • Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers a signal that inhibits IL-2 and IFN- ⁇ production, as well as cell proliferation induced upon T cell receptor activation (Carter et al, Eur J Immunol 2002, 32 (3) : 634-43; Freeman et al, J Exp Med 2000, 192 (7) : 1027-34) .
  • the mechanism involves recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol 2007, 8, 239-245) .
  • Activation of the PD-1 signaling axis also attenuates PKC- ⁇ activation loop phosphorylation, which is necessary for the activation of NF- ⁇ B and API pathways, and for cytokine production such as IL-2, IFN- ⁇ and TNF (Sharpe et al, Nat Immunol 2007, 8, 239-245; Carter et al, Eur J Immunol 2002, 32 (3) : 634-43; Freeman et al, J Exp Med 2000, 192 (7) : 1027-34) .
  • PD-1-deficient mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al, Immunity 1999, 11: 41-151; Nishimura et al, Science 2001, 291: 319-322) .
  • LCMV model of chronic infection it has been shown that PD-1/PD- L1 interaction inhibits activation, expansion and acquisition of effector functions of virus-specific CD8 T cells (Barber et al, Nature 2006, 439, 682-7) .
  • potent small molecules that can have activity as inhibitors of the interaction of PD-L1 with PD-1, and thus may be useful for therapeutic administration to enhance immunity against cancer and/or infectious diseases.
  • These small molecules are expected to be useful as pharmaceuticals with desirable stability, solubility, bioavailability, therapeutic index and toxicity values that are crucial to become efficient medicines to promote human health.
  • the present invention relates to compounds that are used as inhibitors of the functional interaction between PD-L1 and PD-1.
  • Inhibitors of the interaction between PD-L1 and PD-1 are useful in the treatment of cancers and infectious diseases.
  • the compounds of the invention have the general structures as Formula I.
  • Q and Q’ are each independently selected from absent, C (O) or C (R 2 ) 2 ;
  • R 1 and R 10 are each independently selected from H, halogen, CN, or C 1-8 alkyl;
  • R 2 and R 20 are each independently selected from H, or C 1-8 alkyl; or
  • R 1 and R 2 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring;
  • R 10 and R 20 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring
  • R 3 and R 4 are each independently selected from heterocyclic ring or heteroaryl ring optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O, wherein the heterocyclic ring or heteroaryl ring is monocyclic or bicyclic, optionally substituted with C 1-8 alkyl, - (CH 2 ) p -COOH, - (CH 2 ) p -CONR 30 R 40 , - (CH 2 ) p -OH, - (CH 2 ) p -heterocyclyl, -C 3-7 cycloalkyl, -C 3-7 heterocyclyl, or - (CH 2 ) p -NR 30 R 40 , wherein C 1-8 alkyl, - (CH 2 ) p -COOH, - (CH 2 ) p -CONR 30 R 40 , - (CH 2 ) p -OH, - (CH 2 ) p -heterocyclyl,
  • R 30 and R 40 are each independently selected from H, C 1-8 alkyl, -C 3-7 cycloalkyl, or -C 3-7 heterocyclyl; or
  • R 30 and R 40 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring
  • R 21 and R 21 ’ are each independently selected from halogen, CN, OH, COOH, or C 1-8 alkyl;
  • s and p are each independently selected from 0, 1, 2 or 3.
  • Q and Q’ are each independently selected from absent, C (O) or CH 2 .
  • s and p are each independently selected from 0 or 1.
  • R 1 is independently selected from methyl, F or Cl.
  • R 2 is independently selected from H or methyl.
  • R 1 and R 10 together with the atoms to which they are attached form a 5-member heterocyclic ring.
  • R 2 and R 20 together with the atoms to which they are attached form a 5-member heterocyclic ring.
  • R 21 and R 21 ’ are each independently selected from -CH 3 , F, Cl or CN.
  • R 3 and R 4 are each independently selected from which is each unsubstituted or substituted with at least one substituent selected from C 1-6 alkyl, - (CH 2 ) p -COOH, - (CH 2 ) p -CONR 30 R 40 , - (CH 2 ) p -OH, - (CH 2 ) p -heterocyclyl, -C 3- 7 cycloalkyl, -C 3-7 heterocyclyl, or - (CH 2 ) p -NR 30 R 40 , wherein C 1-6 alkyl, - (CH 2 ) p -COOH, - (CH 2 ) p -NH 2 , - (CH 2 ) p -CONR 30 R 40 , - (CH 2 ) p -OH, - (CH 2 ) p -heterocyclyl, -C 3-7 cycloalkyl, -C 3-7 heterocycly
  • R 30 and R 40 are each independently selected from H, C 1-8 alkyl, -C 3-7 cycloalkyl, or -C 3-7 heterocyclyl; or
  • R 30 and R 40 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring.
  • R 30 and R 40 are each independently selected from H, or C 1-3 alkyl.
  • R 3 and R 4 are each independently selected from
  • the compound is of Formula II:
  • R 1 and R 10 are each independently selected from H, halogen, CN, or C 1-8 alkyl;
  • R 2 and R 20 are each independently selected from H, or C 1-8 alkyl; or
  • R 1 and R 2 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring;
  • R 10 and R 20 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring
  • Q and Q’ are each independently selected from absent, C (O) or C (R 2 ) 2 ;
  • X, Y, Z, X’, Y’ or Z’ is independently selected from N, S, O or C;
  • R 5 , R 6 , R 5 ’ and R 6 ’ are each independently selected from (CH 2 ) p -NR 30 R 40 , (CH 2 ) m -cycloalkyl, (CH 2 ) m -heterocyclyl, C 1-8 alkyl, wherein (CH 2 ) p -NR 30 R 40 , (CH 2 ) m -heterocyclyl, C 1-8 alkyl are each unsubstituted or substituted with at least one substituent selected from C 1-8 alkyl, -COOH, -NH 2 , (CH 2 ) m -hydroxyl, or CN; or
  • R 5 and R 6 together with the atoms to which they are attached form a 6-to 7-member heterocyclic ring comprising 1, 2 or 3 hetero atoms independently selected from N, O or S, the heterocyclic ring being unsubstituted or substituted with at least one substituent selected from C 1-8 alkyl, (CH 2 ) m -carboxyl, (CH 2 ) m -hydroxyl, (CH 2 ) m -heterocyclyl, (CH 2 ) m -aryl, (CH 2 ) m -amido, (CH 2 ) m -CN, (CH 2 ) m -CF 3 , (CH 2 ) m -CHF 2 , (CH 2 ) m -CH 2 F, or (CH 2 ) m -NH 2 ; or
  • R 5 ’ and R 6 ’ together with the atoms to which they are attached form a 6-to 7-member heterocyclic ring comprising 1, 2 or 3 hetero atoms independently selected from N, O or S, the heterocyclic ring being unsubstituted or substituted with at least one substituent selected from C 1-8 alkyl, (CH 2 ) m -carboxyl, (CH 2 ) m -hydroxyl, (CH 2 ) m -heterocyclyl, (CH 2 ) m -aryl, (CH 2 ) m -amido, (CH 2 ) m -CN, (CH 2 ) m -CF 3 , (CH 2 ) m -CHF 2 , (CH 2 ) m -CH 2 F, or (CH 2 ) m -NH 2 ;
  • R 30 and R 40 are each independently selected from H, C 1-8 alkyl, -C 3-7 cycloalkyl, or -C 3-7 heterocyclyl; or
  • R 30 and R 40 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring
  • R 21 and R 21 ’ are each independently selected from halogen, CN, OH, COOH, or C 1-8 alkyl;
  • p, s, and m are each independently selected from 0, 1, 2 or 3;
  • R 1 and R 10 are independently selected from H, methyl, F or Cl.
  • R 2 and R 20 are independently selected from H or methyl.
  • R 1 and R 10 together with the atoms to which they are attached form a 5-member heterocyclic ring.
  • R 2 and R 20 together with the atoms to which they are attached form a 5-member heterocyclic ring.
  • R 21 and R 21 ’ are each independently selected from -CH 3 , F, Cl or CN.
  • X and X’ are each independently selected from O, S or N.
  • Y and Y’ are each independently selected from C, S or N.
  • Z and Z’ are each independently selected from C, or N.
  • R 5 and R 5 ’ are each independently selected from –CH 3 ,
  • R 6 and R 6 ’ are each independently selected from absent, H or methyl.
  • the compound is of Formula III:
  • R 1 and R 10 are each independently selected from H, halogen, CN, or C 1-8 alkyl;
  • R 2 and R 20 are each independently selected from H, or C 1-8 alkyl; or
  • R 1 and R 2 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring;
  • R 10 and R 20 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring
  • Q and Q’ are each independently selected from absent, C (O) or C (R 2 ) 2 ;
  • Ring A and Ring A’ are independently a 5-6 membered aromatic heterocyclic ring, which is each unsubstituted or substituted with at least one substituent selected from C 1-8 alkyl, halogen, OH, or CN;
  • Ring B and Ring B’ are independently a 5-7 membered heterocyclic ring, which is each unsubstituted or substituted with at least one substituent selected from C 1- 8 alkyl, - (CH 2 ) p -COOH, - (CH 2 ) p -CONR 30 R 40 , - (CH 2 ) p -OH, - (CH 2 ) p -heterocyclyl, -C 3- 7 cycloalkyl, -C 3-7 heterocyclyl, or - (CH 2 ) p -NR 30 R 40 , wherein C 1-8 alkyl, - (CH 2 ) p -COOH, - (CH 2 ) p -CONR 30 R 40 , - (CH 2 ) p -OH, - (CH 2 ) p -heterocyclyl, -C 3-7 cycloalkyl, -C 3- 7 heterocyclyl, or - (CH 2 )
  • R 30 and R 40 are each independently selected from H, C 1-8 alkyl, -C 3-7 cycloalkyl, or -C 3-7 heterocyclyl; or
  • R 30 and R 40 together with the atoms to which they are attached form a 5-to 6-member heterocyclic ring
  • R 21 and R 21 ’ are each independently selected from halogen, CN, OH, COOH, or C 1-8 alkyl;
  • p and s are each independently selected from 0, 1, 2 or 3.
  • R 1 and R 10 are independently selected from H, methyl F or Cl.
  • R 2 and R 20 are independently selected from H or methyl.
  • R 21 and R 21 ’ are each independently selected from -CH 3 , F, Cl or CN.
  • s and p are each independently selected from 0 or 1.
  • Q and Q’ are the same, R 1 and R 10 are the same, R 2 and R 20 are the same, R 3 and R 4 are the same, R 21 and R 21 ’ are the same.
  • the present invention further provides some preferred technical solutions with regard to compound of Formula (I) , Formula (II) or Formula (III) , wherein the compound is:
  • N N'- ( ( ( [4, 4'-biindoline] -1, 1'-dicarbonyl) bis (5, 6, 7, 8-tetrahydro-4H-5, 8-epiminocyclohepta [d] thiazole-2, 9-diyl) ) bis (ethane-2, 1-diyl) ) dimethanesulfonamide;
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of any of the present invention and a pharmaceutically acceptable excipient.
  • a pharmaceutically acceptable excipient such as hydroxypropyl methyl cellulose.
  • the said compound in a weight ratio to the said excipient within the range from about 0.0001 to about 10.
  • the present invention additionally provided a use of a pharmaceutical composition of Formula (I) or Formula (II) or Formula (III) for the preparation of a medicament for treating a disease in a subject.
  • the present invention further provides some preferred technical solutions with regard to above-mentioned uses.
  • a medicament thus prepared can be used for the treatment or prevention of, or for delaying or preventing onset or progression in, cancer, cancer metastasis, an immunological disorder.
  • the cancer is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.
  • the present invention provided a method of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient a compound of any one of claims 1-12, or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • the present invention provided a method of treating a disease associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • the disease is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.
  • the present invention provided a method of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • the present invention also provides a use of the present compound or its pharmaceutical composition for the preparation of a medicament.
  • the medicament is used for the treatment or prevention of cancer.
  • the cancer is colon cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.
  • the medicament is used as an inhibitor of PD-1/PD-L1 interaction.
  • halogen as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo.
  • halogen groups include F, Cl and Br.
  • alkyl includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, cyclcopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclcobutyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclcopentyl, n-hexyl, 2-hexyl, 2-methylpentyl and cyclohexyl.
  • C 1-8 as in C 1-8 alkyl is defined to identify the group as having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or branched arrangement.
  • Alkenyl and alkynyl groups include straight, branched chain or cyclic alkenes and alkynes.
  • C 2-8 alkenyl and “C 2-8 alkynyl” means an alkenyl or alkynyl radicals having 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or brached arrangement.
  • Alkoxy radicals are oxygen ethers formed from the previously described straight, branched chain or cyclic alkyl groups.
  • aryl refers to an unsubstituted or substituted mono-or polycyclic ring system containing carbon ring atoms.
  • the preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
  • heterocyclyl represents an unsubstituted or substituted stable three to eight membered monocyclic saturated ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O or S, and wherein the nitrogen or sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the heterocyclyl group may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclyl groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
  • heteroaryl represents an unsubstituted or substituted stable five or six membered monocyclic aromatic ring system or an unsubstituted or substituted nine or ten membered benzo-fused heteroaromatic ring system or bicyclic heteroaromatic ring system which consists of carbon atoms and from one to four heteroatoms selected from N, O or S, and wherein the nitrogen or sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the heteroaryl group may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
  • alkenyloxy refers to the group -O-alkenyl, where alkenyl is defined as above.
  • alknyloxy refers to the group -O-alknyl, where alknyl is defined as above.
  • cycloalkyl to a cyclic saturated alkyl chain having from 3 to 12 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclobutyl, cyclobutyl.
  • substituted refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent (s) .
  • the substituent (s) is independently selected from the group consisting of -F, -Cl, -Br, -I, -OH, trifluromethoxy, ethoxy, propyloxy, iso-propyloxy, n-butyloxy, isobutyloxy, t-butyloxy, -SCH 3 , -SC 2 H 5 , formaldehyde group, -C (OCH 3 ) , cyano, nitro, CF 3 , -OCF 3 , amino, dimethylamino, methyl thio, sulfonyl and acetyl.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
  • substituted alkyl group examples include, but not limited to, 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, methoxymethyl, pentafluoroethyl and piperazinylmethyl.
  • substituted alkoxy groups include, but not limited to, aminomethoxy, thrifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, 3-hydroxypropoxy.
  • the compounds of the present invention may also be present in the form of pharmaceutically acceptable salts.
  • the salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts” .
  • the pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • the pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid.
  • organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic.
  • Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
  • the present invention includes within its scope the prodrugs of the compounds of this invention.
  • such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
  • the present invention includes compounds described herein can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
  • the above Formula I and II are shown without a definitive stereochemistry at certain positions.
  • the present invention includes all stereoisomers of Formula I and II and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
  • the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
  • the present invention includes any possible solvates and polymorphic forms.
  • a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
  • water, ethanol, propanol, acetone or the like can be used.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
  • Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous) , ferric, ferrous, lithium, magnesium, manganese (ic and ous) , potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N', N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine,
  • the compound of the present invention When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • citric, hydrobromic, formic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids particularly preferred are formic and hydrochloric acid.
  • the compounds of Formula are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
  • compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds represented by Formula I, or a prodrug, or a metabolite, or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous) .
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion.
  • the compound represented by Formula I, or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I.
  • the compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers include such as sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include such as carbon dioxide and nitrogen.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about l mg to about 2g of the active ingredient, typically 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or l000mg.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
  • dosage levels on the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day.
  • colon cancer, rectal cancer, mantle cell lymphoma, multiple myeloma, breast cancer, prostate cancer, glioblastoma, squamous cell esophageal cancer, liposarcoma, T-cell lymphoma melanoma, pancreatic cancer, glioblastoma or lung cancer may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
  • BSA Bovine serum album
  • DMSO Dimethyl sulfoxide
  • HATU O- (7-azabenzotrizol-1-yl) -N, N, N, N-tetramethyluronium hexafluorophosphate;
  • TFA trifluoroacetic acid
  • THF Tetrahydrofuran
  • Step 1 Preparation of 2-methyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) aniline (M1)
  • Step 2 Preparation of 2, 2'-dimethyl- [1, 1'-biphenyl] -3, 3'-diamine (M2)
  • Step 3 Preparation of di-tert-butyl 2, 2'- ( ( (2, 2'-dimethyl- [1, 1'-biphenyl] -3, 3'-diyl) bis (azanediyl) ) bis (carbonyl) ) bis (6, 7-dihydrothiazolo [5, 4-c] pyridine-5 (4H) -carboxylate) (M3)
  • Step 4 Preparation ofN, N'- (2, 2'-dimethyl- [1, 1'-biphenyl] -3, 3'-diyl) bis (4, 5, 6, 7-tetrahydrothiazolo [5, 4-c] pyridine-2-carboxamide) (Compound 1)
  • Step 1 Preparation of tert-butyl (S) -2- (2- (2-ethoxy-2-oxoacetyl) hydrazine-1-carbonyl) pyrrolidine-1-carboxylate (M3)
  • Step 2 Preparation of ethyl (S) -5- (1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -1, 3, 4-thiadiazole-2-carboxylate (M33)
  • Step 3 Preparation of (S) -5- (1- (tert-butoxycarbonyl) pyrrolidin-2-yl) -1, 3, 4-thiadiazole-2-carboxylic acid (M333)
  • Step 1 Preparation of 4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) indoline (33-1)
  • Step 3 Preparation of 2-4 di-tert-butyl 2, 2'- ( [4, 4'-biindoline] -1, 1'-dicarbonyl) bis (6, 7-dihydrothiazolo [5, 4-c] pyridine-5 (4H) -carboxylate) (33-3)
  • Step 4 Preparation of [4, 4'-biindoline] -1, 1'-diylbis ( (4, 5, 6, 7-tetrahydrothiazolo [5, 4-c] pyridin-2-yl) methanone) (33)
  • Step 1 Preparation of tert-butyl 2- ( (2-methyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl) carbamoyl) -6, 7-dihydrothieno [3, 2-c] pyridine-5 (4H) -carboxylat (34-2)
  • Step 2 Preparation of tert-butyl 2- ( (3-bromo-2-methylphenyl) carbamoyl) -5, 6-dihydroimidazo [1, 2-a] pyrazine-7 (8H) -carboxylate (34-4)
  • Step 3 Preparation of tert-butyl 2- ( (3'- (7- (tert-butoxycarbonyl) -5, 6, 7, 8-tetrahydroimidazo [1, 2-a] pyrazine-2-carboxamido) -2, 2'-dimethyl- [1, 1'-biphenyl] -3-yl) carbamoyl) -6, 7-dihydrothieno [3, 2-c] pyridine-5 (4H) -carboxylate (34-5)
  • Step 4 Preparation of tert-butyl 2- ( (3'- (7- (tert-butoxycarbonyl) -N-methyl-5, 6, 7, 8-tetrahydroimidazo [1, 2-a] pyrazine-2-carboxamido) -2, 2'-dimethyl- [1, 1'-biphenyl] -3-yl) (methyl) carbamoyl) -6, 7-dihydrothieno [3, 2-c] pyridine-5 (4H) -carboxylate (34-6)
  • Step 5 N- (2, 2'-dimethyl-3'- (N-methyl-5, 6, 7, 8-tetrahydroimidazo [1, 2-a] pyrazine-2-carboxamido) - [1, 1'-biphenyl] -3-yl) -N-methyl-4, 5, 6, 7-tetrahydrothieno [3, 2-c] pyridine-2-carboxamide (34)
  • some of examples are used as a starting material, which undergoes the corresponding reaction with other material, such as methyl 2-bromoacetate.
  • other material such as methyl 2-bromoacetate.
  • Step 1 dimethyl 2, 2'- ( ( [4, 4'-biindoline] -1, 1'-dicarbonyl) bis (6, 7-dihydrothiazolo [5, 4-c] pyridine-2, 5 (4H) -diyl) ) diacetate (102)
  • Step 2 2, 2'- ( ( [4, 4'-biindoline] -1, 1'-dicarbonyl) bis (6, 7-dihydrothiazolo [5, 4-c] pyridine-2, 5 (4H) -diyl) ) diacetic acid (103)
  • Example 2 Prepare the following examples (shown in Table 2) essentially as described for Example 1, 33, 34, 102 or 103 using the corresponding starting materials.
  • Example 44 shown in Table 2 essentially as described for Example 1 using instead of and other starting materials are either commercially available or made by known procedures in the reported literature or as illustrated.
  • the present invention also exemplarily provides a method of preparing other compounds, for example, compound 6.
  • Step 1 Preparing of 8-chloro-3-vinyl-1, 7-naphthyridine
  • Step 2 Preparing of (8-chloro-1, 7-naphthyridin-3-yl) methanol
  • Step3 Preparing of (8- ( (3-bromo-2-methylphenyl) amino) -1, 7-naphthyridin-3-yl) methanol
  • Step4 Preparing of (8- ( (2-methyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl) amino) -1, 7-naphthyridin-3-yl) methanol
  • Step5 Preparing of ( ( (2, 2'-dimethyl- [1, 1'-biphenyl] -3, 3'-diyl) bis (azanediyl) ) bis (1, 7-naphthyridine-8, 3-diyl) ) dimethanol
  • Step6 Preparing of 2- ( ( (8- ( (3'- ( (3- ( (2-hydroxyethyl) amino) -1, 7-naphthyridin-8-yl) amino) -2, 2'-dimethyl- [1, 1'-biphenyl] -3-yl) amino) -1, 7-naphthyridin-3-yl) methyl) amino) ethan-1-ol
  • the compound 167 was synthesized with M167 according to the method described above.
  • Step 2 Preparation of tert-butyl 2- ( (2-methyl- [1, 1'-biphenyl] -3-yl) carbamoyl) -6, 7-dihydrothiazolo [5, 4-c] pyridine-5 (4H) -carboxylate (M22)
  • Step 3 Preparation of N- (2-methyl- [1, 1'-biphenyl] -3-yl) -4, 5, 6, 7-tetrahydrothiazolo [5, 4-c] pyridine-2-carboxamide (Comparative Example 1)
  • the assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 ⁇ L. Inhibitors were first serially diluted in DMSO and then added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assays were carried out at 25°C in the PBS buffer (pH 7.4) with 0.05%Tween-20 and 0.1%BSA. Recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosy stems (PD1-H5229) .
  • Recombinant human PD-1 protein (25-167) with Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257) .
  • PD-L1 and PD-1 proteins were diluted in the assay buffer and 10 ⁇ L was added to the plate well. Plates were centrifuged and proteins were preincubated with inhibitors for 40min. The incubation was followed by the addition of 10 ⁇ L of HTRF detection buffer supplemented with Europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and anti-His antibody conjugated to -Allophycocyanin (APC, PerkinElmer-AD0059H) .
  • APC PerkinElmer-AD0059H
  • IC 50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
  • IC 50 values in the following ranges: “*” stands for “IC 50 ⁇ 25nM” ; “**” stands for “25nM ⁇ IC 50 ⁇ 100nM” ; “***” stands for “100nM ⁇ IC 50 ⁇ 200nM” ; “****” stands for “IC 50 >200nM” .
  • Example 4 Data obtained for the Example compounds using the PD-1/PD-L1 homogenous time-resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 4.
  • Table 4 Data obtained for the Example compounds using the PD-1/PD-L1 homogenous time-resolved fluorescence (HTRF) binding assay described in Example A is provided in Table 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), des procédés d'utilisation des composés en tant qu'immunomodulateurs, et des compositions pharmaceutiques comprenant de tels composés. Les composés sont utiles dans le traitement, la prévention ou l'amélioration de maladies ou de troubles tels que le cancer ou les infections.
EP19780810.8A 2018-04-03 2019-04-03 Immunomodulateurs, compositions et procédés associés Withdrawn EP3774750A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018081776 2018-04-03
CN2018083808 2018-04-19
CN2018085256 2018-05-02
CN2018095508 2018-07-12
PCT/CN2019/081192 WO2019192506A1 (fr) 2018-04-03 2019-04-03 Immunomodulateurs, compositions et procédés associés

Publications (2)

Publication Number Publication Date
EP3774750A1 true EP3774750A1 (fr) 2021-02-17
EP3774750A4 EP3774750A4 (fr) 2021-12-29

Family

ID=68099858

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19780810.8A Withdrawn EP3774750A4 (fr) 2018-04-03 2019-04-03 Immunomodulateurs, compositions et procédés associés

Country Status (6)

Country Link
US (1) US20210040118A1 (fr)
EP (1) EP3774750A4 (fr)
JP (1) JP2021520342A (fr)
KR (1) KR20210010979A (fr)
CN (1) CN111936475B (fr)
WO (1) WO2019192506A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3005727A1 (fr) 2015-11-19 2017-05-26 Incyte Corporation Composes heterocycliques de 2-methylbiphenyle-3-yl substitue et compositions pharmaceutiques connexes utiles comme immunomodulateurs
PE20230731A1 (es) 2015-12-22 2023-05-03 Incyte Corp Compuestos heterociclicos como inmunomoduladores
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
PE20190731A1 (es) 2016-06-20 2019-05-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
CN109803651B (zh) 2016-06-27 2022-05-31 凯莫森特里克斯股份有限公司 免疫调节剂化合物
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
BR112019012957A2 (pt) 2016-12-22 2019-11-26 Incyte Corp derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
EP3558989B1 (fr) 2016-12-22 2021-04-14 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
KR102647257B1 (ko) 2017-07-28 2024-03-13 케모센트릭스, 인크. 면역조절제 화합물
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
CN111448189A (zh) * 2018-02-05 2020-07-24 上海和誉生物医药科技有限公司 一种联芳基衍生物、其制备方法和在药学上的应用
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2019165043A2 (fr) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines utiles en tant qu'antagonistes de pd-l1
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
MX2021013819A (es) 2019-05-15 2022-02-10 Chemocentryx Inc Compuestos de triarilo para el tratamiento de enfermedades asociadas a pd-l1.
CA3139242A1 (fr) 2019-06-20 2020-12-24 Viengkham Malathong Composes pour le traitement de maladies pd-l1
WO2021007386A1 (fr) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes en tant qu'inhibiteurs de pd-l1
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
EP4043461A1 (fr) * 2019-09-30 2022-08-17 Medshine Discovery Inc. Composé utilisé comme inhibiteur de pd-1/pd-l1 à petites molécules et application associée
KR20220083775A (ko) 2019-10-16 2022-06-20 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아민
AU2020368393A1 (en) 2019-10-16 2022-04-21 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
CN110950865B (zh) * 2019-12-16 2022-05-17 诚达药业股份有限公司 一种医药中间体8-氯-1,7-萘啶-3-甲醛合成方法
US20230105212A1 (en) * 2020-01-03 2023-04-06 Shanghai Hansoh Biomedical Co., Ltd. Biphenyl derivative inhibitor, preparation method therefor and use thereof
US20230111910A1 (en) * 2020-01-21 2023-04-13 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof
CN113248492B (zh) * 2020-02-10 2022-11-08 上海海雁医药科技有限公司 杂环取代的含氮六元杂环衍生物及其制法与医药上的用途
CN113493469A (zh) * 2020-03-18 2021-10-12 成都倍特药业股份有限公司 可作为免疫调节剂的化合物、其制备方法和应用
WO2021228000A1 (fr) * 2020-05-11 2021-11-18 上海长森药业有限公司 Préparation d'un dérivé hétérocyclique aromatique lié à un cycle biaryle en tant qu'immunomodulateur et son utilisation
WO2021248231A1 (fr) * 2020-06-09 2021-12-16 Relive Therapeutics Inc. Composés comprenant un noyau à trois cycles en tant que bloqueurs de pd-1/pd-l1
CA3182595A1 (fr) * 2020-06-17 2021-12-23 Mingming Zhang Immunosuppresseur, son procede de preparation et son utilisation
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022099075A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Forme cristalline d'un inhibiteur pd-1/pd-l1
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022152316A1 (fr) * 2021-01-18 2022-07-21 南京明德新药研发有限公司 Dérivé de biphényle et son utilisation
TW202241893A (zh) * 2021-03-30 2022-11-01 大陸商南京明德新藥研發有限公司 四氫萘啶化合物晶型、鹽型及其製備方法
TW202340165A (zh) * 2022-03-07 2023-10-16 大陸商上海和譽生物醫藥科技有限公司 一種全對稱聯苯基衍生物及其製備方法和應用
CN116283971B (zh) * 2023-03-13 2024-04-12 沈阳药科大学 含稠合杂环结构的吲哚啉类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10242940A1 (de) * 2002-09-16 2004-03-18 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen
KR101116756B1 (ko) * 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
SG11201610195UA (en) * 2014-07-16 2017-01-27 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
PE20190731A1 (es) * 2016-06-20 2019-05-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
CN109195602B (zh) * 2016-08-03 2022-01-07 上海齐鲁制药研究中心有限公司 用作免疫调节剂的对称或半对称化合物
MA46045A (fr) * 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2899402T3 (es) * 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
BR112019012957A2 (pt) * 2016-12-22 2019-11-26 Incyte Corp derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
US20180179202A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CN111386116B (zh) * 2017-08-18 2022-06-14 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
CN111448189A (zh) * 2018-02-05 2020-07-24 上海和誉生物医药科技有限公司 一种联芳基衍生物、其制备方法和在药学上的应用

Also Published As

Publication number Publication date
US20210040118A1 (en) 2021-02-11
KR20210010979A (ko) 2021-01-29
CN111936475B (zh) 2024-05-10
WO2019192506A1 (fr) 2019-10-10
EP3774750A4 (fr) 2021-12-29
JP2021520342A (ja) 2021-08-19
CN111936475A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
EP3774750A1 (fr) Immunomodulateurs, compositions et procédés associés
CN112384500B (zh) 免疫调节剂及其组合物和制备方法
WO2020156323A1 (fr) Immunomodulateurs, compositions et procédés associés
AU2013216721B2 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
IL294048A (en) sos1 inhibitors
EP3466929B1 (fr) Composés hétérocycliques utiles comme inhibiteurs de pdk1
CN116003321A (zh) 可用作shp2抑制剂的新型杂环衍生物
CN112566900B (zh) 免疫调节剂及其组合物和制备方法
EP3503891A1 (fr) Inhibiteurs d'indoleamine 2,3-dioxygénase et leurs méthodes d'utilisation
WO2019193540A1 (fr) Dérivés hétéroaryles de formule (i) utilisés en tant qu'inhibiteurs d'atf4
EP3119765A1 (fr) Inhibiteurs de syk de type hétéroaryle
JP2020525513A (ja) 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
CN112424167A (zh) 化学化合物
JP2009531274A (ja) キナーゼ阻害性ピロロピリジン化合物
CN113166156B (zh) 酪氨酸激酶抑制剂、组成及其方法
CN112969694B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
EP3849972A1 (fr) Immunomodulateurs, compositions et procédés associés
AU2019339703B2 (en) Immunomodulators, compositions and methods there of
WO2024120471A1 (fr) Composés ciblant un mutant de p53
EA044307B1 (ru) Иммуномодуляторы, их композиции и способы применения
JP2024509466A (ja) 複素環ｒｉｐ１キナーゼ阻害剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211125

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20211119BHEP

Ipc: A61P 35/00 20060101ALI20211119BHEP

Ipc: A61P 37/00 20060101ALI20211119BHEP

Ipc: A61K 31/395 20060101ALI20211119BHEP

Ipc: A61K 31/38 20060101ALI20211119BHEP

Ipc: A61K 31/33 20060101ALI20211119BHEP

Ipc: C07D 471/04 20060101ALI20211119BHEP

Ipc: C07D 417/02 20060101ALI20211119BHEP

Ipc: C07D 413/14 20060101ALI20211119BHEP

Ipc: C07D 403/14 20060101ALI20211119BHEP

Ipc: C07D 277/60 20060101AFI20211119BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220625